ATTRv-PN clinical trials at UCSF

1 research study open to eligible people

ATTRv-PN is an inherited condition where transthyretin protein builds up and damages nerves. UCSF is running a study that follows people over months and years to note changes. UCSF is recording exams, lab tests, and patient symptoms for research files.

Showing trials for

  • Patients With Transthyretin (ATTR) Amyloidosis

    open to eligible people ages 18-130

    The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.

    San Francisco, California and other locations

Last updated: